Product Data Sheet

Ebselen

Cat. No.: HY-13750 CAS No.: 60940-34-3 Molecular Formula: C₁₃H₉NOSe Molecular Weight: 274.18

HIV; Calcium Channel; Virus Protease; Phosphatase Target:

Pathway: Anti-infection; Membrane Transporter/Ion Channel; Neuronal Signaling; Metabolic


Enzyme/Protease

Storage: Powder -20°C 3 years

> 4°C 2 years

In solvent -80°C 1 year

> -20°C 6 months



SOLVENT & SOLUBILITY

In Vitro

DMSO: 50 mg/mL (182.36 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	3.6472 mL	18.2362 mL	36.4724 mL
	5 mM	0.7294 mL	3.6472 mL	7.2945 mL
	10 mM	0.3647 mL	1.8236 mL	3.6472 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (9.12 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (9.12 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	Ebselen (SPI-1005), a glutathione peroxidase mimetic, is a potent voltage-dependent calcium channel (VDCC) blocker ^{[1][2]} . Ebselen potently inhibits M ^{pro} (IC ₅₀ =0.67 μ M) and COVID-19 virus (EC ₅₀ =4.67 μ M) ^[3] . Ebselen is an inhibitor of HIV-1 capsid CTD dimerization. Ebselen, an organoselenium compound, can permeate the blood-brain barrier and has anti-inflammatory, antioxidant and anticancer activity ^{[4][5]} .
IC ₅₀ & Target	HIV-1
In Vitro	Ebselen (SPI-1005; 0.4-100 μ M; 20-24 hours) shows strong antiviral effects at a concentration of 10 μ M treatment in COVID-19 virus infected Vero cells. Ebsele covalently binds to C145 of the catalytic dyad in COVID-19 virus Mpro ^[3] .

?Ebselen inhibits early viral postentry events of the HIV-1 life cycle by impairing the incoming capsid uncoating process^[4]. ?Ebselen permeates the blood-brain barrier and inhibits endogenous inositol monophosphatase in mouse brain. Ebselen inhibits inositol monophosphatase (IMPase)^[5].

?Ebselen inhibits QSOX1 enzymatic activity and suppresses invasion of pancreatic, renal cancer cell lines^[6].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR^[3]

Cell Line:	COVID-19 virus infected Vero cells	
Concentration:	0.4, 1.2, 3.7, 11.1, 33.3, 100 μM	
Incubation Time:	20-24 hours	
Result:	Showed strong antiviral effects at a concentration of 10 μM treatment.	

In Vivo

Ebselen (5, 10 mg/kg; IP) decreases 5-HT₂ agonist-induced head twitches in a dose-dependent manner^[5].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	20-25 g 10-12 week old male C57Bl6 mice ^[5]	
Dosage:	5, 10 mg/kg	
Administration:	IP	
Result:	Decreased 5-HT ₂ agonist-induced head twitches in a dose-dependent manner.	

CUSTOMER VALIDATION

- Biomaterials. 24 August 2022, 121757.
- Environ Int. 2022 Jun 1;165:107327.
- Int J Antimicrob Agents. 2019 Dec;54(6):814-819.
- Antiviral Res. 2023 Apr 17;105606.
- Antiviral Res. 2019 Jun 27;169:104544.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Thenin-Houssier S, et al. Ebselen, a Small-Molecule Capsid Inhibitor of HIV-1 Replication. Antimicrob Agents Chemother. 2016 Mar 25;60(4):2195-208.
- $\hbox{\cite{commun.}\cite{commun$
- [3]. Hanavan PD, et al. Ebselen inhibits QSOX1 enzymatic activity and suppresses invasion of pancreatic and renal cancer cell lines. Oncotarget. 2015 Jul 30;6(21):18418-28.
- [4]. Liang Q, et al. Electrical Stimulation Degenerated Cochlear Synapses Through Oxidative Stress in NeonatalCochlear Explants. Front Neurosci. 2019 Oct 14;13:1073.
- [5]. H Sies, et al. Ebselen, a Selenoorganic Compound as Glutathione Peroxidase Mimic
- [6]. Jin Z, et al. Structure of M^{pro} from COVID-19 virus and discovery of its inhibitors. Nature. 2020 Apr 9.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 3 of 3 www.MedChemExpress.com